HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. - Wikidata - wikimedia - TriplyDB

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

http://www.wikidata.org/entity/Q33513977

about

Immunovirological parameters and cytokines in HIV infection Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution Association of low level viremia with inflammation and mortality in HIV-infected adults Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability.Immune activation and HIV persistence: implications for curative approaches to HIV infection.A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study.Persistent immune activation in chronic HIV infection: do any interventions work?Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy.Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation The role of cytokines in the establishment, persistence and eradication of the HIV reservoir Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy Factors Associated with the Size of HIV DNA Reservoir.Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient.HIV reservoirs and strategies for eradication.Immunodiscordant responses to HAART--mechanisms and consequences.Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.Potential implication of residual viremia in patients on effective antiretroviral therapy.Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection Discordance between peripheral and colonic markers of inflammation during suppressive ART Factors associated with a strictly undetectable viral load in HIV-1-infected patients.Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns.Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals.Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.

P2860

Q26829264-4C3D0AAF-E6E8-4DCC-A925-42E3F564938E Q27021524-D0A2A9CA-C5D8-4D5B-87AF-38E18C5DD750 Q28539563-4082121D-A852-47F5-91C4-49478EC83B4E Q28743237-62040450-C5FF-4BCA-BC2B-2E2C1C5B7F95 Q33653518-24D7BB9D-5C79-453E-8D18-643F36841F94 Q34057868-7B67968F-8206-4990-AEB4-72D441C0F5D3 Q34195386-70B2654B-DB1C-48FD-8623-9D5557E905ED Q34244228-EDAE3AAF-94F2-4DA3-9A4F-0468728251E1 Q34351320-33EBB645-AB72-4466-9C15-1CFEBE3D838C Q34743336-B69E912C-1E33-4AC2-B1F4-3698A0460BBE Q34749335-0F6A02E4-74EF-4C1D-8BA6-39644FE8BD7C Q34851102-2EA1B784-3287-4EC7-8A59-C3C36387CA63 Q35109483-70900334-AC34-4CF6-8107-EAF6A8E5B1E0 Q35185674-3C66F5D3-38F9-4EB5-90C9-39E656A7AC1C Q35640599-31F09234-C49B-4665-A980-FD33A9F03645 Q35698144-BD0EA34D-3F7E-4795-829D-F112D002C4B4 Q35808100-038F0E9F-F63A-4624-8300-B2CD4860251E Q35946786-43E4278B-58C9-44D9-8DA0-1B66CAA0D4D0 Q36047903-4D2A4B4C-11F2-4234-8414-F6F0ABF316D8 Q36379299-F857AE6B-2F9C-4E2B-A122-7AAA30F92BB4 Q36930492-0B7B900A-79D2-4166-B1A1-0A1647C1243A Q37157209-932AF63A-663D-4F80-B44B-E224D9B6CD4E Q37308125-D4F4F162-188A-467C-8592-02A78FF509F4 Q37418140-B07158E1-81F1-41CC-8CB8-B0D36CC35077 Q37513027-7B5EACA7-DF21-4FA0-80A0-B3DC5E29C1B7 Q37615584-7B6CEB39-BFE2-41EF-906B-2DF6601444D3 Q37673623-2516BDAF-21A0-4744-8AAC-24EE4E9247F3 Q37976293-3E75CD16-A30F-4B5C-B79E-6BF5A874881C Q38156230-9464D6D1-9789-450E-BEBD-338EED63345E Q38164430-D92DE949-0F91-4955-B3DC-C28FF4D34BF9 Q38271917-E4BBA265-40F5-4C6B-8D23-C27766C2637D Q38411418-671E978A-D02F-4B6E-B47E-E28CC9DD79A6 Q38749963-B26D1980-64D7-4F36-985C-48A9078FC3BD Q38930864-214626EA-C1A7-483D-AFAA-5367F8DEB92A Q39219128-55F9E1BD-DF23-4C86-81D2-39FB212C4DFE Q40060728-BF3478A4-E2F6-46AA-BA00-EF052884BD1E Q40075058-F65D753F-DA4D-4910-BE6A-E369B768307D Q40699445-A3437910-09D4-4B9A-8967-6C1F439C7E88 Q40789003-6F842E56-F850-46F1-A79B-353837B8E64E Q40922638-040EE866-B79F-45FF-96F7-5E54FB15D202

P2860

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

http://www.wikidata.org/entity/Q33513977

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@ast

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@en

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@nl

type

label

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@ast

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@en

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@nl

prefLabel

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@ast

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@en

HIV-1 residual viremia correla ...... nation antiretroviral therapy.

@nl

P1433

Q33513977-2D28DD79-A756-4249-A4FB-114344FAE4B1

P1476

Q33513977-D4595AFA-352C-4AD4-B787-4EA4EAC040CE

P2093

Q33513977-0260A97D-62D8-419B-B4BF-D11E3C2F2AAE

Q33513977-136A7E23-DF8B-450B-A35B-5A65013F1928

Q33513977-59C50375-C3E8-42E8-846E-2FBB9C541016

Q33513977-9888CE88-06D3-4124-AB07-99D6CC9E09C2

Q33513977-AA5A55F5-C924-4679-A926-20E1E5E30228

Q33513977-CB09ECE8-679C-4CA9-BDF9-06207EF5B4DC

Q33513977-CDCE7B97-6E5C-4BA9-9096-265FD790FF3D

P2860

Q33513977-03FD0698-1117-4E9B-9508-6A9405272A6D

Q33513977-06760F51-2C9B-4E3B-B9CD-2E910509B4A4

Q33513977-0C46A877-C817-4F2E-9C1F-A297F33E50EC

Q33513977-0E227F39-4D90-488B-A738-40326E0B6755

Q33513977-0ED452E3-AF93-4CEC-AFD9-AAD134A3D9B6

Q33513977-14E11D96-DAE5-493C-A7A6-4D6F7E5612C0

Q33513977-15AC1F53-41A9-4DC2-B494-798F5C54FC89

Q33513977-1A06351F-4BEA-40A7-811D-D2FB5E7F0210

Q33513977-207A1FC2-C4C0-4AEC-ADFD-9ABDDDEA7338

Q33513977-20D128D6-D927-491E-B1EC-D577F165E45E

P304

Q33513977-51607CB0-8455-48BD-B0C0-C4C8F9D27EB7

P31

Q33513977-0A0640EE-FF89-46B8-B08A-9043E0554080

P356

Q33513977-C9091513-288A-4ABC-8B43-5B575487B7E6

P407

Q33513977-58A57123-808E-4617-8A30-1AD81E923578

P433

Q33513977-4B7B0A87-E92B-49B1-99F8-137BC1C5C640

P478

Q33513977-39BBC928-0B73-4455-B004-E81A38FBEE6B

P50

Q33513977-1CD5799B-965C-40CC-A07A-FB5D2A064DE7

Q33513977-DDB67FA8-CE39-46B5-9583-790CB27DE6D3

Q33513977-F1E402A4-877C-41FE-BBB1-46CFA7E8B551

P577

Q33513977-151D1828-9A6F-499C-B272-56BF99F43A06

P5875

Q33513977-9128379D-39AB-417B-ADC1-2128889E18AD

P698

Q33513977-154269AE-1CB1-476C-9A65-609CE7D15845

P921

Q33513977-4CA54658-159B-4844-9F31-1EC3E6B032D7

P932

Q33513977-78F8136F-E472-4C8D-A00F-80991CEB777C

P356

JOURNAL.PONE.0007658

P1433

P1476

HIV-1 residual viremia correla ...... ination antiretroviral therapy

@en

P2093

Bruno Marchou

http://www.w3.org/2001/XMLSchema#string

Fatima-Ezzahra L'faqihi-Olive

http://www.w3.org/2001/XMLSchema#string

Jacques Izopet

http://www.w3.org/2001/XMLSchema#string

Martine Dubois

http://www.w3.org/2001/XMLSchema#string

Maud Mavigner

http://www.w3.org/2001/XMLSchema#string

Michelle Cazabat

http://www.w3.org/2001/XMLSchema#string

Patrice Massip

http://www.w3.org/2001/XMLSchema#string

P2860

Expression and function of chemokine receptors on human thymocytes: implications for infection by human immunodeficiency virus type 1.

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

Viral dynamics in human immunodeficiency virus type 1 infection

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

P304

e7658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0007658

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Christophe Pasquier

Stéphanie Raymond

P577

2009-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38054849

http://www.w3.org/2001/XMLSchema#string

P698

19876401

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2765414

http://www.w3.org/2001/XMLSchema#string